Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension.
The 4th World Symposium on Pulmonary Hypertension was the first international meeting to focus not only on pulmonary arterial hypertension (PAH) but also on the so-called non-PAH forms of pulmonary hypertension (PH). The term "non-PAH PH" summarizes those forms of PH that are found in groups 2 to 5 of the current classification of PH, that is, those forms associated with left heart disease, chronic lung disease, recurrent venous thromboembolism, and other diseases. Many of these forms of PH are much more common than PAH, but all of them have been less well studied, especially in terms of medical therapy. The working group on non-PAH PH focused mainly on 4 conditions: chronic obstructive lung disease, interstitial lung disease, chronic thromboembolic PH, and left heart disease. The medical literature regarding the role of PH in these diseases was reviewed, and recommendations regarding diagnosis and treatment of PH in these conditions are provided. Given the lack of robust clinical trials addressing PH in any of these conditions, it is important to conduct further studies to establish the role of medical therapy in non-PAH PH.
Hoeper
Marius M
MM
Department of Respiratory Medicine, University of Hannover Medical School, Hannover, Germany. Electronic address: hoeper.marius@mh-hannover.de.
Barberà
Joan Albert
JA
Department of Respiratory Medicine, Hospital Clinic, CIBERES, University of Barcelona, Barcelona, Spain.
Channick
Richard N
RN
Division of Pulmonary and Critical Care Medicine, University of California, San Diego, La Jolla, California.
Hassoun
Paul M
PM
Department of Medicine, Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Lang
Irene M
IM
Division of Cardiology, Medical University of Vienna, Vienna, Austria.
Manes
Alessandra
A
Institute of Cardiology, University of Bologna, Bologna, Italy.
Martinez
Fernando J
FJ
Division of Pulmonary and Critical Care Medicine; University of Michigan Health System, Ann Arbor, Michigan.
Naeije
Robert
R
Department of Pathophysiology, Free University of Brussels, Brussels, Belgium.
Olschewski
Horst
H
Department of Pulmonology, Medical University of Graz, Graz, Austria.
Pepke-Zaba
Joanna
J
Pulmonary Vascular Disease Unit, Papworth Hospital, Cambridge, United Kingdom.
Redfield
Margaret M
MM
Department of Cardiology, Mayo Clinic, Rochester, Minnesota.
Robbins
Ivan M
IM
Department of Allergy, Pulmonary and Critical Care Medicine; Vanderbilt University Medical Center, Nashville, Tennessee.
Souza
Rogério
R
Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.
Torbicki
Adam
A
Department of Chest Medicine, Institute of Tuberculosis and Lung Diseases, Medical University of Warsaw, Warsaw, Poland.
McGoon
Michael
M
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
D000465:Algorithms; D015897:Comorbidity; D005541:Forced Expiratory Volume; D006333:Heart Failure / Q000453:epidemiology; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D017563:Lung Diseases, Interstitial; D029424:Pulmonary Disease, Chronic Obstructive / Q000453:epidemiology / Q000503:physiopathology; D011655:Pulmonary Embolism; D012307:Risk Factors